Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial,
Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
Liliana H. Mochmann, Martin Neumann, Eva K. von Der Heide, Verena Nowak, Anja A. Kühl, Jutta Ortiz-Tanchez, Juliane Bock, Wolf K Hofmann, Claudia D Baldus
Published Dec 4, 2013 · Vol. 5, No. 2 · pp. 351-362
Andrew D Beggs, Enric Domingo, Megan McGregor, Mikael Presz, Elaine Johnstone, Rachel Midgley, David Kerr, Dahmane Oukrif, Marco Novelli, Muti Abulafi, Shirley V Hodgson, Wakkas Fadhil, Mohammed Ilyas, Ian P Tomlinson
Published Oct 28, 2012 · Vol. 3, No. 11 · pp. 1348-1355
Melissa L. Sokolosky, Kristin M. Stadelman, William H. Chappell, Stephen L. Abrams, Alberto M. Martelli, Franca Stivala, Massimo Libra, Ferdinando Nicoletti, Lyudmyla B. Drobot, Richard A. Franklin, Linda S. Steelman, James A. McCubrey
Published Jul 1, 2011 · Vol. 2, No. 7 · pp. 538-550
Keywords: Akt, mTOR, Targeted Therapy, Drug Resistance